DNA X Appoints Executive Chairman Mike Mulica as Acting CEO, Grants Substantial RSU Packages to Key Executives
summarizeSummary
DNA X, Inc. appointed Mike Mulica as Acting CEO, filling a recent vacancy, and approved substantial RSU grants and salary increases for him and CFO Clay Crolius, providing leadership stability during a strategic pivot.
check_boxKey Events
-
Acting CEO Appointed
Mike Mulica, previously Executive Chairman, was appointed Acting Chief Executive Officer, effective February 9, 2026, filling the vacancy created by the recent CEO resignation on February 5, 2026.
-
Substantial RSU Grant and Salary Increase for Acting CEO
Mr. Mulica's annual base salary was increased to $450,000, and he was granted 50,000 restricted stock units (RSUs), valued at approximately $350,500 based on the current stock price, vesting over one year.
-
CFO Receives RSU Grant and Change in Control Acknowledgment
CFO Clay Crolius received a grant of 35,000 RSUs, valued at approximately $245,350, also vesting over one year. The company also acknowledged the January 23, 2026 asset sale as a 'triggering event' (Change in Control) under his employment agreement.
-
Executive Incentivization
The total RSU grants to the Acting CEO and CFO amount to approximately $595,850, representing a significant incentive package for key leadership during the company's strategic pivot.
auto_awesomeAnalysis
This filing addresses the critical leadership vacuum created by the recent CEO resignation, appointing Mike Mulica, previously Executive Chairman, as Acting CEO. The company also approved substantial RSU grants and salary increases for Mr. Mulica and a significant RSU grant for CFO Clay Crolius. These compensation packages, representing a material portion of the company's market capitalization, are crucial for incentivizing and retaining key leadership during a period of significant strategic transition following the sale of its 5G business and pivot to digital assets. The acknowledgment of the asset sale as a 'Change in Control' for the CFO's agreement further clarifies executive employment terms.
At the time of this filing, SONM was trading at $7.01 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $2.52 to $61.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.